Ovid Therapeutics (OVID) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 57.1% versus a loss of 68.9%. Over five years, OVID leads with a -32.5% price change compared with -76.5% for PHAT. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $378.8 million), about 1.1 times the size.
Phathom Pharmaceuticals converts more of its revenue into profit, with a net margin of -126.3% versus -240.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OVID | PHAT |
|---|---|---|
| Share price | $2.20 | $4.66 |
| Market cap | $415.21M | $378.82M |
| 1-day change | -5.98% | -8.27% |
| YTD return | +34.97% | -71.91% |
| 1-year return | +57.14% | -68.93% |
| 5-year return | -32.52% | -76.46% |
| Forward P/E | — | 5.18 |
| EPS (TTM) | $-0.15 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.25M | $175.11M |
| Revenue growth (YoY) | +1181.27% | +216.93% |
| Net income (latest FY) | $-17.41M | $-221.25M |
| Gross margin | — | 87.09% |
| Operating margin | -585.20% | -91.36% |
| Net margin | -240.13% | -126.35% |
| 52-week high | $3.11 | $18.31 |
| 52-week low | $1.26 | $4.62 |
| Distance from 52-week high | -29.15% | -74.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +179.55% | +321.67% |
| Average volume | 1.98M | 1.45M |
| Shares outstanding | 188.73M | 81.29M |
| Employees | 23 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed PHAT by 126.1 percentage points over the past year.
- Phathom Pharmaceuticals is more profitable, keeping -126.3 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +216.93%).
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
OVID vs PHAT FAQ
Which is bigger, Ovid Therapeutics or Phathom Pharmaceuticals?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $378.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, OVID or PHAT?
OVID returned +57.14% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Ovid Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.